45 reports of this reaction
2.9% of all ALLOPURINOL SODIUM reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for ALLOPURINOL SODIUM, manufactured by Hikma Pharmaceuticals USA Inc.. There are 45 FDA adverse event reports linking ALLOPURINOL SODIUM to DYSPNOEA. This represents approximately 2.9% of all 1,553 adverse event reports for this drug.
Patients taking ALLOPURINOL SODIUM who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for ALLOPURINOL SODIUM, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for ALLOPURINOL SODIUM:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 45 FDA reports for ALLOPURINOL SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.9% of all adverse event reports for ALLOPURINOL SODIUM, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking ALLOPURINOL SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.